A gel matrix engineered for the oral mucosa.
The gel holds peptides against the mucosa under the tongue and inside the cheek, a vascular route to the bloodstream designed to sidestep gut degradation and first-pass metabolism. GRAS-status ingredients, made in a no-heat process.
Five mechanisms, working together.
The working hypothesis: delivery improves through several complementary effects rather than a single permeation enhancer. Each is an active area of research.
- 01
Biointerface modulation
Interacts with membrane lipids and proteins to open more opportunities for transport across the mucosa.
- 02
Enhanced permeation
Supports transport of larger molecules, shown with high-molecular-weight hyaluronic acid.
- 03
Mucoadhesive matrix
Holds the dose against the mucosa for longer, increasing contact and residence time.
- 04
Ionic interactions
Charge-based effects between the gel, the peptide and the membrane. A research hypothesis.
- 05
Molecular organisation
The no-heat process shapes how actives are dispersed and presented, and protects peptide stability.
Large molecules, across a human tissue barrier.
Permeation (ng/mL)
- 216
- 254
- 160
- 527
- UNTREATED
- HA ALONE
- HA + RAW
- HA + GELTIDES
What we've seen in people so far.
- RCT
Randomised controlled trial (nutrient formulation)
RANDOMISED · DOUBLE-BLIND · PLACEBOImproved blood cell counts and sleep quality, with no adverse effects reported.Early-stage data. Full summaries under NDA.
- 5 min
Nutrient uptake
HUMAN EVALUATIONDetected in blood within 5 minutes, with effects sustained for 30 minutes. A nutrient study, not a peptide study.Early-stage data. Full summaries under NDA.
- RBC
Clinical evaluation (blood health formulation)
CLINICAL EVALUATIONImproved haemoglobin saturation, red blood cell morphology and rheology.Early-stage data. Full summaries under NDA.
- NDA
Peptide observational data
UNDER NDAObservational peptide data is available to partners under NDA.Early-stage data. Full summaries under NDA.
Figures reflect supplied study summaries. Observational cohorts are early signals, not controlled trials. Peptide-specific pharmacokinetic studies are [IN PROGRESS / PLANNED]. Full summaries are shared with qualified partners under NDA.
Building the peptide-specific data set.
Partners in our pilot programme get early access to every study as it reads out.
- [Q1 2027]Peptide permeation across mucosal tissue models
- [Q2 2027]Pharmacokinetic study: NAD+ sublingual gel vs injection
- [Q2 2027]Stability programme for all 8 launch SKUs
- [Q3 2027]Partner pilot adherence and outcomes read-out
- [Q4 2027]Peer-reviewed publication of platform data